Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors

This study tests two drugs — olaparib (a PARP inhibitor) and durvalumab (an immunotherapy) — together in patients with tumors that have an IDH gene mutation. IDH mutations affect how cells use energy and are found in certain brain tumors and bile duct cancers. **You may be eligible if...** - You are 18 or older and weigh more than 30 kg - You have IDH-mutant diffuse brain tumor (astrocytic or oligodendroglial type) with no more than 2 prior treatment regimens after first relapse (Cohort A), OR - You have IDH-mutant bile duct cancer (cholangiocarcinoma) with no more than 2 prior regimens for advanced disease (Cohort B) - Your organ and bone marrow function are within normal range **You may NOT be eligible if...** - Your tumor does not have an IDH mutation - You have received more than 2 prior treatment regimens - Your organ function is not adequate Talk to your doctor to see if this trial is right for you.